Introduction
The initial discovery of cellular senescence dates back to the demonstration that primary human diploid fibroblasts, when cultured in vitro, have a finite capacity for growth, followed by an irreversible arrest of the cell cycle (Hayflick and Moorhead, 1961) . This phenomenon, known as 'replicative senescence' because it correlates with telomere attrition (Harley et al., 1990) , has since been observed in multiple cell types from several different organisms (Collado and Serrano, 2010) . The definition of cellular senescence has expanded to include the phenotypically similar growth arrest caused by various other sources of cellular stress, including DNA damage and oxidative stress (Serrano and Blasco, 2001) . Another form, called oncogene-induced cellular senescence, was first described in mouse and human primary cultured fibroblasts overexpressing RasV12 (Serrano et al., 1997) . These cells underwent a growth arrest, accompanied by morphological changes typically associated with cellular senescence, including a large, flattened cellular morphology, and positive staining for senescence-associated bgalactosidase (Kuilman et al., 2010) .
The in vivo relevance of cellular senescence as a barrier to tumour progression was first shown in a transgenic model of the E2F3 transcription factor (Lazzerini Denchi et al., 2005) . When ectopically expressed in the pituitary gland, E2F3 led to initial hyperplasia followed by the induction of cellular senescence. The subsequent discovery of senescent cells in growth-arrested human benign naevi, or moles, which frequently possess oncogenic mutations in the protein kinase BRAF, but rarely develop into malignant melanomas, was another striking example (Michaloglou et al., 2005) . A concurrent study, in which RasV12 was conditionally expressed in the mouse lung, also showed the relevance of cellular senescence in vivo (Collado et al., 2005) . These mice developed multiple pre-neoplastic lung adenomas, and displayed infrequent progression to neoplastic adenomas. Significantly, while the pre-malignant cells displayed markers of cellular senescence, these markers were absent in the malignant adenocarcinoma cells. Several studies have gone on to firmly establish that the cellular senescence response is a key tumour suppressive mechanism that acts to block the progression of preneoplastic lesions to full blown prostate Majumder et al., 2008) , colon (Bartkova et al., 2006; Kuilman et al., 2008; Fujita et al., 2009; Bennecke et al., 2010) , lymph (Braig et al., 2005) , and breast (Swarbrick et al., 2008) cancers. Taken together, these studies have established that cellular senescence is, like apoptosis, an inherent cellular defense that acts as a barrier to tumour progression. This review will describe the key molecular pathways that control cellular senescence, focusing on recent findings with regard to the transcriptional regulation of these pathways. We will discuss how these transcriptional regulators are perturbed in human cancer and how molecular insights into their function can be best exploited for future cancer therapies.
Molecular pathways controlling cellular senescence
The retinoblastoma protein (pRb) and p53 tumour suppressor pathways represent the core signalling pathways involved in the induction of cellular senescence (Lowe and Sherr, 2003; Narita and Lowe, 2005; Collado and Serrano, 2010) . Consistent with this, members of these pathways are well-known oncogenes and tumour suppressors and are frequently genetically disrupted in cancer (Figure 1 ).
The tumour suppressive p53 transcription factor is required for cellular senescence, and mutation or deletion of the TP53 gene occurs in more than half of human cancers (Hollstein et al., 1994) . Wild-type p53 accumulates in response to cellular stresses, and activates a specific program of target genes to restrict the growth of abnormal or damaged cells by inducing one of three outcomes: apoptosis, a transient cell cycle arrest or a permanent cell cycle arrest (cellular senescence). The outcome reached is thought to depend on the type and level of stress signal involved, and the cellular context (Riley et al., 2008; Vousden and Prives, 2009) . Transcriptional target genes of p53 include the cyclin-dependent kinase (CDK) inhibitor p21, the proapoptotic genes BAX and APAF1, and the E3 ubiquitin ligase MDM2 (Vousden and Lu, 2002; Riley et al., 2008) . MDM2 negatively regulates the levels of p53, forming a regulatory feedback loop (Haupt et al., 1997; Kubbutat et al., 1997) . The upstream p14
Arf protein (p19 Arf in mice) in turn prevents the degradation of p53 (Sherr, 2006) . It is not fully understood how p53 plays a role in cellular senescence, but its ability to transactivate the p21 promoter, leading to the accumulation of p21 protein, is well established as a means by which p53 can induce growth arrest (Levine, 1997; Vousden and Prives, 2009 ). The p21 protein primarily acts by the inhibition of cyclin/CDK complexes upstream of pRb. This inhibition leads to a reduction in pRb phosphorylation, increased association of pRb with E2F1-3 and repression of E2F target genes. Interestingly, in mouse fibroblasts, the loss of p21 does not recapitulate p53 loss, and these cells still undergo cellular senescence (Pantoja and Serrano, 1999) . In contrast, in human fibroblasts, p21 loss was reported to lead to immortalisation (Brown et al., 1997) . However, it was not clear if p53 was functional in the cells used in this study. Therefore, it seems likely that p53 has additional target genes that are important in cellular senescence control. Two potential candidates are the direct p53 target genes PAI-1 and miR-34 (Kortlever et al., 2006; He et al., 2007) . Supporting this role, the suppression of PAI-1 confers bypass of senescence, whereas ectopic expression of either PAI-1 or miR34 leads to the induction of cellular senescence.
The RB1 gene (pRb protein) was initially identified as a tumour suppressor owing to its inactivation in a childhood eye tumour called retinoblastoma (Burkhart and Sage, 2008) . Its tumour suppressor activity is mainly attributed to its ability to bind and inactivate the E2F family of transcription factors, which transactivate genes encoding cell cycle proteins and DNA replication factors required for cell growth (Bracken et al., 2004; Blais and Dynlacht, 2007) . pRb is a member of the pocket protein family along with the related proteins p107 and p130 (Classon and Harlow, 2002) . The pocket proteins are substrates for cyclin/CDK complexes, which phosphorylate them, releasing the E2F transcription factors, and allowing progression through the cell cycle (Classon et al., 2000) . The CDKs are themselves inhibited by the CDK inhibitors p16
INK4a and p15 INK4b , both of which are upregulated during cellular senescence (Collado and Serrano, 2006) , leading to reduced phosphorylation of pRb, and E2F inactivation. This results in the accumulation of heterochromatin around E2F-responsive promoters in senescent cells, stably silencing E2F-regulated genes and forming what are known as senescence-associated heterochromatic foci (SAHF) (Narita et al., 2003) .
It is likely that pRb possesses more tumour suppressive activity than the other pocket proteins, as mutations affecting p107 and p130 are very rarely observed in Figure 1 Molecular mechanisms of cellular senescence. The p53 and pRb pathways are central to cellular senescence control. Recent evidence suggests that multiple types of cellular stress can activate the p53 pathway by common or at least partially overlapping mechanisms. Telomere attrition, radiation, cytotoxic drugs and oncogene-induced DNA replication stress have all been shown to induce the DNA damage response (DDR), resulting in the activation of the checkpoint kinases ATM/ATR and CHK1/2, and leading to p53 accumulation. p53 can also be activated downstream of p14 ARF , which binds to the E3 ubiquitin ligase, MDM2, preventing the degradation of p53. MDM2 can directly bind to p53 and control its transcriptional function, as well as regulate degradation of p53 through ubiquitination. This stabilisation and accumulation of p53 allows the activation of downstream genes such as p21
CIP1
, and the induction of cellular senescence or apoptosis, depending on the cellular context. The p16
INK4a tumour suppressor, transcriptionally upregulated in stressed cells, inhibits cyclin D-dependent kinases, thereby preventing the phosphorylation and inactivation of the retinoblastoma protein, pRb. This promotes the repressive association between pRb and the E2F1-3 pro-proliferative transcriptional activators, preventing progression through the cell cycle, and permitting the formation of a repressive or 'closed' chromatin structure around E2F target gene promoters, known as SAHF. The mechanisms of transcriptional regulation of p16
INK4a and p14 ARF in senescent human cells are not yet fully understood (red, tumour suppressors; green, oncogenes).
Transcriptional regulation of cellular senescence F Lanigan et al human cancers (Burkhart and Sage, 2008) . Indeed, pRb seems to play a non-redundant role in tumour suppression by permanent repression of E2F target genes during cellular senescence, but not quiescence, meaning that loss of pRb, but not p107 or p130, results in a defective senescence response (Sage et al., 2003; Chicas et al., 2010) .
The INK4A-ARF locus Strikingly, both the p16 INK4a and p14 Arf proteins are encoded by the same alternatively spliced gene locus, called the CDKN2A or INK4A-ARF locus (Quelle et al., 1995; Gil and Peters, 2006) . Although it is unclear as to how exactly the unusual gene arrangement of INK4A-ARF came to be, its design means that, by mutating or silencing this locus, cells can simultaneously disrupt the Rb and p53 pathways, thus bypassing cellular senescence. It is therefore not surprising that this is one of the most commonly mutated, deleted and epigenetically silenced genomic regions in human tumours (Gil and Peters, 2006; Esteller, 2008) .
To date, many of our insights into the role of the INK4A-ARF locus in cellular senescence have been derived from mouse models or mouse primary culture lines. However, the main difficulty in using mice to define cellular senescence pathways in tumourigenesis is that, although in mice, the bypass of cellular senescence appears to occur primarily through loss of the Arf-p53 signalling axis, the INK4A-pRb pathway seems to be more important in human cells. This is supported by epidemiological data showing high levels of mutations affecting p16
INK4A as opposed to p14 ARF in human tumours (Gil and Peters, 2006) . Voorhoeve and Agami (2003) elegantly addressed this question in vitro in primary human fibroblasts using small interfering RNAs targeted to p16 INK4A and p14 Arf separately. They found that loss of p16
INK4a and p53 can synergise to promote transformation, whereas loss of p14
Arf , while enhancing the rate of proliferation, does not replace loss of p53 in a transformation assay. Taken together, these data suggest that p16
INK4a is the major tumour suppressor of the INK4A-ARF locus in human cells, acting in concert with p53 to protect from oncogenic transformation. However, recent reports have also proposed a more central role for mouse p16
Ink4a in some situations, including the progression of colorectal cancers and melanoma (Bennecke et al., 2010; Carragher et al., 2010; Monahan et al., 2010) , Interestingly, no evidence to date supports the notion that in human cells, like in mouse cells, p14
ARF is transcriptionally activated in response to stress (Wei et al., 2001; Voorhoeve and Agami, 2003) . Collectively, the data described above highlights the relevance of the INK4A gene in senescence induction. 
Transcriptional regulation of the INK4A-ARF locus
Polycomb group proteins (PRC1 and PRC2) In 1999, seminal work by Jacobs et al. first showed that polycomb group proteins are critical for the transcriptional repression of the INK4A-ARF locus. Indeed, mouse embryonic fibroblasts deficient for the polycomb group protein BMI1 underwent premature cellular senescence, due to the derepression of both the INK4A and ARF genes (Jacobs et al., 1999) . The polycomb group proteins are chromatin remodellers that function to repress gene expression by shaping chromatin structure (Sparmann and van Lohuizen, 2006; Bracken and Helin, 2009) . They combine to form the polycomb repressive complexes PRC1, composed of a PC (Polycomb) protein (for example, CBX7/CBX8), a PSC (Posterior sex combs) protein (for example, BMI1/ MEL18), a RING (Really Interesting New Gene) protein, a PH (Polyhomeotic) protein and an SCML (Sex combs on mid-leg) protein; and PRC2, composed of EED, SUZ12 and EZH2 in mammals (Muller and Verrijzer, 2009; Simon and Kingston, 2009 ).
The PRC2 component EZH2 catalyses the trimethylation of lysine 27 on histone H3 (H3K27me3), a mark involved in the recruitment of the PRC1 complex by recognition of the H3K27 mark by the chromobox domain in the CBX protein (Figure 2a ). This facilitates gene silencing, most likely through chromatin remodelling (Bracken and Helin, 2009 ). In addition to BMI1, two additional PRC1 components, CBX7 and CBX8, have been shown to extend the lifespan of cells by repression of the INK4A-ARF locus (Gil et al., 2004; Dietrich et al., 2007) . Conversely, knockdown of the polycomb components CBX7, CBX8, BMI1 or MEL18 results in INK4A derepression and proliferative arrest. (Jacobs et al., 1999; Itahana et al., 2003; Gil et al., 2004; Dietrich et al., 2007; Maertens et al., 2009) . Interestingly, polycomb group proteins are also essential for stem cell self-renewal in both mice and humans (Lessard and Sauvageau, 2003; Molofsky et al., 2003; Park et al., 2003; Cales et al., 2008) , and this is in part due to their ability to bind and repress the INK4A-ARF locus.
Polycombs regulate INK4A-ARF, by directly binding to and 'blanketing' the complete INK4A-ARF locus, an association that is necessary for maintaining transcriptional repression in unstressed cells Dietrich et al., 2007; Kotake et al., 2007) . Recently, a long non-coding RNA (ncRNA) called ANRIL was shown to be required, in addition to the H3K27me3 mark, for the recruitment of the PRC1 complex to the INK4A-ARF locus (Yap et al., 2010) . ANRIL is one example of a long ncRNA from a family that are emerging as recruiters of chromatin remodelling complexes to target genes Mercer et al., 2009) . ANRIL is transcribed in cis from within the Transcriptional regulation of cellular senescence F Lanigan et al INK4B-ARF-INK4A locus, binds to CBX7, and this, in addition to the H3K27me3 epigenetic mark, contributes to its binding to the locus (Yap et al., 2010) . Indeed, point mutations that disrupt CBX7's ability to bind to either ANRIL or the H3K27me3 mark impair its ability to repress INK4A and ARF and to prevent senescence induction. However, this model conflicts with previous studies, which reported a positive correlation between expression levels of ANRIL, p16
INK4A and p19 ARF (Pasmant et al., 2007; Liu et al., 2009) . Recently, the putative RNA helicase MOV10 has also been implicated in the recruitment of the PRC1 complex (MessaoudiAubert et al., 2010) . MOV10 knockdown displaces polycombs from the INK4A-ARF locus, and results in the upregulation of p16
INK4a
. Taken together, these data imply that RNA-based mechanisms have an important role in PRC1 recruitment.
Interestingly, transcription factors have also been implicated in the regulation of the INK4A-ARF locus. For example, the zinc-finger protein Zfp277 is reported to be involved in the transcriptional repression of the INK4A and ARF genes through recruitment of PRC1, by direct interaction with Bmi1 (Negishi et al., 2010) . Zfp277 associates with the INK4A-ARF locus in mouse embryonic fibroblasts, an association that decreases upon serial passaging. The loss of Zfp277 is correlated with the progressive displacement of polycomb association with the INK4A-ARF locus, and increased mRNA expression of INK4A and ARF. The ectopic expression of Bmi1 in Zfp277 À/À mouse embryonic fibroblasts fails to bypass cellular senescence, showing the importance of Zfp277 in polycomb-mediated regulation of the locus.
In contrast to what is described for PRC1, little is known about the mechanisms of PRC2 recruitment to the INK4A-ARF locus. However, it is also likely that long ncRNAs and sequence-specific transcription factors are involved. Supporting this, recent work has identified 49000 ncRNAs, which have been shown to bind to the PRC2 complex by RNA immunoprecipitation Figure 2 Transcriptional regulation of the INK4A locus. Polycomb group proteins directly bind to and regulate the INK4A locus, facilitating repression of the INK4A gene in unstressed cells. Although the mechanism by which polycombs are recruited to specific regions of DNA is unclear, we know that, once recruited, these proteins act to stably silence gene expression by altering chromatin structure. Some examples of emerging mechanisms by which polycomb group proteins are recruited to and maintained at the INK4A locus in unstressed cells are outlined: (a) EZH2 catalyses the H3K27me3 epigenetic mark, which promotes recruitment of the PRC1 complex; (b) recruitment of the PRC1 complex is also partly dependent on the association of the CBX7 component with the long ncRNA ANRIL; and (c) the transcription factor Zfp277 binds directly to the BMI1 component of the PRC1 complex and is partially responsible for its recruitment to the INK4A locus. In senescent cells, polycomb proteins are lost or displaced from the INK4A locus by a number of established mechanisms, including (d) EZH2 downregulation resulting in the loss of H3K27 methylation, (e) the histone demethylase JMJD3, which actively removes the H3K27me3 mark and (f) the SWI/SNF chromatin remodelling complex, which is proposed to displace polycombs from the INK4A locus. We also propose a novel mechanism (g) by which polycomb proteins may be displaced by transcriptional activators. The mechanisms described here, while referring to the INK4A promoter, may also be relevant to the p14 ARF and p15 INK4b promoters.
Transcriptional regulation of cellular senescence F Lanigan et al (Khalil et al., 2009; Zhao et al., 2010) . Alternatively, or perhaps complementary to this, sequence-specific transcription factors may contribute to the recruitment and maintenance of the PRC2 complex on the locus in unstressed cells. Although numerous studies have shown correlations between the expression of various transcription factors and INK4A and ARF levels, reliable evidence of direct binding to DNA around the locus by chromatin immunoprecipitation assay is required to definitively show a direct link. Transcriptional regulators that have been reported to repress the INK4A and ARF genes expression include the T-box transcription factor TBX2, a potent repressor of mouse ARF (Jacobs et al., 2000) , and the transcriptional co-repressor CtBP, which has been implicated as a direct repressor of human INK4A expression (Mroz et al., 2008) . Recent work has also implicated an N-terminal fragment of the GLI2 transcription factor in the repression of INK4A by direct binding to its promoter (Bishop et al., 2010) . Although these factors are known repressors of the INK4A-ARF locus, further work is required to evaluate their potential interplay with polycomb group proteins.
Stress-induced derepression of the INK4A-ARF locus
A key feature of cellular senescence in response to cellular stress is the displacement of polycomb repression complexes from the INK4A-ARF locus . In stressed cells, the key H3K27me3 methyltransferase, EZH2, an E2F target gene, is downregulated, leading to a loss of H3K27me3 on the locus, and consequent displacement of the BMI1 containing PRC1 complex (Bracken et al., 2003 Chen et al., 2009 ). An alternative, or perhaps complementary, mechanism of INK4A transcriptional activation has been proposed to occur upon RAS activation (Agger et al., 2009; Barradas et al., 2009) . The histone demethylase JMJD3 is upregulated, recruited to the INK4A-ARF locus and actively removes the H3K27me3 mark, thereby leading to PRC1 displacement and consequent gene activation. Chromatin remodelling factors have also been shown to play a role in displacing polycombs from the INK4A-ARF locus, including the SWI/SNF complex (Kia et al., 2008) , and the trithorax protein MLL1, which functionally antagonises polycombs by catalysing the transcriptionally active H3K4me3 mark (Kotake et al., 2009) . Regulation of the stability of the PRC1 complex also appears to be another facet, as the de-ubiquitination of the PRC1 components BMI1 and MEL18 by the ubiquitin-specific proteases 7 and 11 has been shown to increase their abundance , whereas the loss of these ubiquitin-specific proteases promotes INK4A transcriptional activation.
Transcriptional activators of the INK4A-ARF locus
In stressed cells, the loss of polycomb proteins from the INK4A-ARF locus is thought to lead to an opening of the chromatin state , a configuration that allows for loading and induction by DNA binding transcriptional activators. Candidates include Ets1 and Ets2, which directly bind to the INK4A promoter and activate INK4A expression in senescent human diploid fibroblasts (Ohtani et al., 2001) . Interestingly, the ability of Ets2 to activate INK4A can be blocked by binding to the basic helix-loop-helix protein ID1. In agreement with this, RasV12-induced cellular senescence in the mouse mammary gland can be bypassed by the additional overexpression of Id1 (Swarbrick et al., 2008) . Furthermore, mouse embryonic fibroblasts derived from Id1-deficient mice express high levels of INK4A (Lyden et al., 1999; Alani et al., 2001) , suggesting that a balance between Ets2 and Id1 expression is maintained in unstressed cells, which can be perturbed by increased Ets2 activity upon oncogenic RasV12 activation, resulting in increased INK4A expression.
Other potential transcriptional activators of the INK4A-ARF locus include MEOX2, a homeobox transcription factor (Irelan et al., 2009) , MITF, a transcriptional regulator expressed in melanocytes (Loercher et al., 2005) , and HMG-box containing protein 1 . Supporting a role for MITF as an activator of INK4A expression, it was reported to bind to the INK4A promoter in normal human melanocytes. Furthermore, overexpression of MITF in a mouse embryonic cell line resulted in the upregulation of INK4A and inhibition of cellular growth, which could be bypassed by INK4A inactivation (Loercher et al., 2005) . Recent work has reported that the transcription factor HMG-box containing protein 1 binds to the INK4A promoter in senescent late passage or RasV12 overexpressing human lung fibroblasts . Consistent with this, knockdown of HMG-box containing protein 1 impaired both the induction of senescence and INK4A transcriptional activation, and was required for RasV12-induced cellular transformation. Reduced levels of HMG-box containing protein 1 mRNA correlates with relapse of human breast tumours (Zhang et al., 2006) , suggesting a possible role as a tumour suppressor. Additional regulators of the locus include members of the E2F family of transcriptional regulators, which can both activate (E2F1-3) and repress (E2F3b) ARF but not INK4A (Aslanian et al., 2004; Komori et al., 2005; del Arroyo et al., 2007) . However, although the transcriptional regulators discussed here are known to bind to and regulate INK4A-ARF, the precise mechanisms of how their activities relate to polycomb protein function still remain to be elucidated.
Epigenetic regulation of the INK4A-ARF locus
The INK4A promoter is epigenetically silenced by DNA hypermethylation in a range of human tumour types (Merlo et al., 1995; Esteller et al., 2001) . This loss can also occur in histologically normal mammary tissues in healthy women, supporting the notion that transcriptional and epigenetic alterations are among the earliest events in cancer (Holst et al., 2003; Feinberg et al., 2006) . Studies on early-stage human cancers have shown that INK4A expression is frequently lost upon the transition from pre-neoplastic to invasive lesions (Collado et al., 2005; Bartkova et al., 2006; Fujita et al., 2009; Bennecke et al., 2010) .
One possible mechanism by which this might happen is that polycomb group proteins are somehow misregulated in cancer, leading to the aberrant epigenetic silencing of the INK4A-ARF locus. Supporting this hypothesis, both EZH2 and CBX7 are reported to recruit DNA methyltransferases to target gene promoters (Vire et al., 2006; Schlesinger et al., 2007; Mohammad et al., 2009) . Although this has not been demonstrated for the INK4A promoter, it does suggest a scenario whereby polycombs can directly contribute to the altered DNA methylation profiles present in tumours. In fact, polycomb target genes are as much as 12 times more likely to become aberrantly silenced by DNA methylation in cancer compared with nonpolycomb target genes (Ohm et al., 2007; Schlesinger et al., 2007; Widschwendter et al., 2007) . Furthermore, poorly differentiated and aggressive human tumours show preferential repression of polycomb target genes (Ben-Porath et al., 2008) . This is reflected in the fact that polycombs and their recruiters are altered in a number of tumour types. For example, BMI1 is amplified or overexpressed in non-Hodgkin's lymphoma (Bea et al., 2001; Sauvageau and Sauvageau, 2010) . Furthermore, the levels of both CBX7 and ANRIL are elevated in prostate cancer tissues, concurrent with a decrease in INK4A expression levels (Yap et al., 2010) , which would seem to contradict the previously mentioned reports of a positive correlation between ANRIL, INK4A and ARF (Pasmant et al., 2007; Liu et al., 2009) . Similarly, EZH2 is amplified or overexpressed and correlated with poor prognosis in several cancer types, including prostate, breast and melanoma (Bracken et al., 2003; Kleer et al., 2003; Bachmann et al., 2006) , and SUZ12 is overexpressed in lymphoma and melanoma, and translocated in some endometrial cancers (Koontz et al., 2001; Martin-Perez et al., 2010) . This frequent upregulation of polycomb proteins and cofactors such as ncRNAs and transcription factors could trigger the aberrant silencing of the INK4A-ARF locus observed in multiple cancer types. However, there are some contradictory reports, which suggest that polycomb expression can be decreased in certain tumour types, including the loss of CBX7 in thyroid and pancreatic cancers (Pallante et al., 2008; Karamitopoulou et al., 2010) , the loss of BMI1 in endometrial carcinoma and melanoma (Bachmann et al., 2008; Engelsen et al., 2008) and the inactivation of EZH2 in myeloid disorders (Ernst et al., 2010) . These studies challenge the idea that tumourigenesis is exclusively associated with an increase in polycomb function, and imply that any imbalance in polycomb activity, resulting in altered expression of polycomb target genes, may have tumour-promoting effects.
Transcriptional regulation downstream of pRb
The remarkably stable state of cellular senescence is thought to be maintained by compacted heterochromatic or 'closed' chromatin, called SAHF, which accumulates around genes encoding cell cycle and proliferation proteins (Narita et al., 2003) (Figure 3) . Mechanistically, the pRb protein functions to recruit repressive enzymatic activities to E2F-regulated target gene promoters. These include histone deacetylases, which remove permissive acetyl groups from histones (Brehm et al., 1998; Luo et al., 1998; Magnaghi-Jaulin et al., 1998) ; DNA methyltransferases (Robertson et al., 2000) , which methylate DNA and help to repress transcription; and histone methyltransferases, including SUV39H1, which tri-methylates lysine 9 on histone H3 (H3K9me3) (Rea et al., 2000; Nielsen et al., 2001; Vandel et al., 2001) . The H3K9me3 mark then acts as a binding site for the chromodomain of the heterochromatin-associated protein HP1g Lachner et al., 2001 ), which in turn promotes the recruitment of chromatin remodellers such as HMGA2 (Narita et al., 2006) , and variant histones such as Transcriptional regulation of cellular senescence F Lanigan et al macroH2A histone (Zhang et al., 2005) . All of this results in the formation of heterochromatin around E2F-responsive promoters, the so-called 'SAHF', and the stable transcriptional silencing of a subset of E2F-regulated, proliferation-associated genes. It is still unclear as to whether SAHF formation requires sustained p16-pRb activation, to allow the gradual heterochromatinisation of E2F target genes. Significantly, in contrast to the transient, reversible repression of E2F-regulated genes seen in quiescent cells, which is mediated by p107 and p130, these genes are stably repressed in senescent cells and do not respond to E2F1 expression (Narita et al., 2003) . The formation of SAHFs is relevant to cancer, and defects in components of the SAHF machinery result in an impaired cellular senescence response and increased tumour formation. For example, the loss of the Suv39h1 histone methyltransferase in mice expressing activated N-Ras in the haematopoietic compartment (Em-N-Ras) leads to accelerated lymphomagenesis compared to control mice (Braig et al., 2005) . Significantly, the cancer cells were apoptosis competent, but were incapable of undergoing cellular senescence. This suggests that H3K9 methylation by Suv39h1 is essential for chromatin compaction and formation of SAHF. A recent study showed that pRb primarily targets E2F target gene promoters in senescent human diploid fibroblasts, supporting the notion that repression of E2F target genes is the main function of pRb in senescent cells (Chicas et al., 2010) . However, pRb is known to bind a variety of additional transcription factors, including c-JUN, Pax3 and C/EBPb (Morris and Dyson, 2001) , and the importance of these associations, and potentially others, in relation to cellular senescence remains to be investigated.
Perspectives
Although our knowledge of the factors involved in cellular senescence control has expanded in recent years, there are a number of key questions that remain to be answered. Firstly, what are the crucial p53 target genes that mediate cellular senescence? How exactly is the INK4A-ARF locus derepressed upon the induction of cellular senescence? Does the contribution of polycombs, ncRNAs and transcription factors to the regulation of INK4A vary depending on the stress involved or cell lineage type? How is the INK4A-ARF locus epigenetically silenced in cancer? Does pRb regulation of SAHF formation involve additional pRB-associated transcription factors?
Therapeutically, although tumour cell death may well be a preferable end point, the induction of cellular senescence could prove to be a viable alternative approach (Shay and Roninson, 2004) . Previously, the study of apoptosis revealed several promising new molecules, which can be targeted in cancer therapies (Reed, 2006; Taylor et al., 2008) . For example, treatments aimed at downregulating anti-apoptotic molecules such as BCL2 and survivin are currently in clinical development, being tested both alone and in combination with existing chemotherapeutic treatments (Call et al., 2008) . It is likely that by studying the mechanisms of cellular senescence, we will uncover novel therapeutic targets that, when manipulated, may induce cellular senescence in tumour cells. Cellular senescence has been reported to be induced following chemotherapeutic treatment of both human and mouse tumours, and, along with apoptosis, may be a clinically beneficial end point to chemotherapy (Schmitt et al., 2002; te Poele et al., 2002; Haugstetter et al., 2010) . In this regard, pharmacological reactivation of p53 has been proposed as an effective therapeutic intervention, as re-induction of p53 expression in malignant tumours in mice leads to rapid tumour regression owing to the induction of cellular senescence or apoptosis, depending on the tumour type (Ventura et al., 2007; Xue et al., 2007) . In humans, the reactivation of p53 could be achieved in tumour cells using specific therapies such as the smallmolecule MDM2 inhibitor Nutlin-3a, which can induce p53 expression in tumours with a still functional p53 (Vassilev et al., 2004; Kumamoto et al., 2008) . This would likely activate transcription of downstream genes, resulting in the induction of apoptosis or cellular senescence. However, recent work has cast doubt on the therapeutic potential of p53 reactivation, suggesting that this strategy may only be effective in late-stage tumours, leaving early lesions that are likely to become cancerous intact (Feldser et al., 2010; Junttila et al., 2010) .
'Epigenetic therapies' such as DNA-demethylating agents and histone deacetylase inhibitors have shown some efficacy as cancer therapeutics (Schmitt, 2007) , mainly due to their capacity to induce a cellular senescence response and derepress INK4A and other tumour suppressors (Timmermann et al., 1998; Matheu et al., 2005) . However, the effects of these agents are potentially very broad and they may have unintended consequences. For example, in the Em-N-Ras transgenic mice discussed previously (Braig et al., 2005) , combined treatment with the histone deacetylase inhibitor trichostatin A and the DNA-demethylating agent 2-deoxy-5-azacytidine was found to promote the development of T-cell lymphomas. The apparent tumour-promoting activity of these treatments is at odds with their clinical success in the treatment of cancer (Gore et al., 2006) . This study highlights the complex nature of epigenetic modifications, and the need for caution with regard to the use of 'general' epigenetic therapies, which could potentially affect the expression of a multitude of genes in both normal and cancer cells. The search for more specific epigenetic-based therapies has identified the histone methyltransferase inhibitor 3-deazaneplanocin A as having efficacy in decreasing EZH2 levels. This results in the inhibition of H3K27 methylation, the reactivation of polycomb target genes, including INK4A, and the induction of growth inhibition and apoptosis in tumour cells in vitro (Tan et al., 2007; Fiskus et al., 2009; Puppe et al., 2009; Hayden et al., 2010; Yamaguchi et al., 2010) . However, the fact that EZH2 is known to be mutated and inactivated in myeloid disorders (Ernst et al., 2010) suggests that Transcriptional regulation of cellular senescence F Lanigan et al EZH2-targeting drugs may only be effective in a subset of tumour types.
Clearly, there is a need for the development of additional, more specific epigenetic therapies. Established regulators of INK4A, such as polycombs, ncRNAs and transcription factors, in theory provide excellent targets. Practically, transcription factors, although not generally ideal targets due to an abundance of protein-protein interaction sites and a lack of hydrophobic pockets, can be specifically targeted by drugs such as small-molecule inhibitors (Darnell, 2002; Tan et al., 2007; Moellering et al., 2009) . Long ncRNAs on the other hand, as they do not code for protein, may require alternative strategies, such as antisense oligonucleotides (Wahlestedt, 2006) . With regard to the future development of drugs targeting these factors, one issue to consider is the lineage-specific expression of transcription factors and ncRNAs that regulate the INK4A-ARF locus (for example, MITF), meaning that drugs targeting a specific transcription factor or ncRNA may not be effective in inducing cellular senescence in all tumour types.
Collectively, the work discussed in this review confirms that transcription factors, chromatin remodellers and long ncRNAs are emerging as being centrally involved in coordinating the activation and maintenance of the senescent state. Future studies aimed at further unravelling new players, delineating their functional interplay with existing factors and examining their function in different cell lineages will be crucial to fully understand the mechanisms of cellular senescence. Finally, this information must be harnessed for clinical benefit, unlocking the potential of these mediators of senescence as therapeutic targets in cancer.
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